Compare Eli Lilly And Co (LLY) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nucor Corporation — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Nucor Corporation trades at $251 (market cap $55.84B). The key difference: Eli Lilly And Co is far larger — about 18.6× Nucor Corporation's market cap, and Nucor Corporation pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nucor Corporation for 78 Days on average.
| LLY | NUE | |
|---|---|---|
Market Cap | $1.04T | $55.84B |
Volume | 3,064,878 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $274.74 |
52-Week Low | $799.57 | $131.78 |
Typical Hold Time | 93 Days | 78 Days |
Enterprise Value | $1.09T | $60.25B |
Dividend Yield | 0.59% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Nucor (NUE) trades at $250.33, up 1.58% with a mixed technical picture showing bearish moving averages but neutral oscillators. The company delivered strong Q2 2026 earnings of $4.84 EPS, beating expectations, and projects higher Q3 earnings on improved steel pricing. Revenue has stabilized at $32.49B in 2025 after declines from 2022 peaks, with net margins improving to 7.99%. Analyst consensus remains positive with a $266.88 price target and 57.58% buy ratings.
Nucor presents a balanced opportunity with strong operational performance and shareholder returns through dividends, though facing headwinds from competitive pressures and cyclical steel demand. The stock's valuation appears reasonable with P/E of 19.64 and P/S of 1.56, but investors should monitor execution against Q3 guidance and industry capacity expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
